Aggressive B-cell lymphomas are occurring with increasing incidence among individuals infected with human immunodeficiency virus (HIV). Several lines of evidence implicate both Epstein-Barr virus (EBV) and c-myc activation in the pathogenesis ofa major subset ofthese tumors.
Human immunodeficiency virus (HIV)-infected individuals are at increased risk for development of fatal polyclonal B-cell lymphoproliferative disorders (1) and aggressive B-cell non-Hodgkin lymphomas (2) . Serial biopsies of lymph nodes from HIV-seropositive patients indicate a progression from polyclonal B-cell proliferation to lymphoma (3) , with both types of cell frequently carrying Epstein-Barr virus (EBV) genomes (4) . c-myc deregulation is another manifestation of many AIDS-related clonal B-cell disorders (4) . Neoplastic conversion of B cells may involve cooperative effects of these two phenomena. EBV can immortalize but not transform B lymphocytes (5) . c-myc has a similar growthperturbing but nontransforming effect in most systems (6) , although it may directly lead to malignant transformation in certain hematopoietic cells (7) . However, introduction of activated c-myc into EBV-infected B cells may lead to tumorigenicity as assessed by growth in agar, in low serum, and in nude mice (8) .
HIV may be involved in these processes, either directly or through extracellular gene products. With this concern, we have investigated interactions among EBV, c-myc, and HIV in peripheral B cells as well as immortalized B-cell lines. Albeit only 5% at most of peripheral B lymphocytes express detectable levels of the high-affinity HIV receptor CD4 (9) , most human B-cell lines can be infected with HIV-1 regardless of the presence of EBV genomes or CD4 expression (10, 11) . This may relate to a very low level of membrane CD4, as infection may be blocked by anti-CD4 monoclonal antibodies in lines that lack detectable antigen (12) . Alternatively, it may involve low-affinity receptors such as C3 and Fc (13) .
We demonstrate here that circulating B lymphocytes are susceptible to HIV infection, similar to their immortalized counterparts. We also present evidence that HIV plays a direct role, at least in vitro, in initiating and maintaining transformation of B lymphocytes through a coupling of deregulation of c-myc expression with activation of EBV transforming proteins.
MATERIALS AND METHODS
Cells. Peripheral mononuclear cells were isolated from heparinized venous blood by Ficoll/Hypaque densitygradient centrifugation, monocytes were depleted by plastic adherence, and T cells were removed by rosetting with neuraminidase-treated sheep erythrocytes (14) . When this procedure is, used, the B-lymphocyte pool typically contains <1% CD3+ T cells, <0.5% esterase-positive monocytes, and >95% surface immunoglobulin-positive cells. Viral Infections. B lymphocytes (2 x 106 cells per well) were exposed to 1 x 105 transforming units of B95-8 EBV, or 1 x 104 50%o tissue culture infectious doses (multiplicity of infection, 0.005) of HIV-1/IIIB for 2 hr at 37°C, followed by washing and resuspension in fresh culture medium.
Membrane Immunofluorescence Assays. Indirect immunofluorescence and cytofluorimetry were performed as described (15) using the following monoclonal antibodies (mAbs): anti-CD3 (mAb 454.3), anti-latent membrane protein (LMP) (kindly supplied by D. A. Thorley-Lawson, Tufts Univ. School of Medicine, Boston), anti-CD23 (mAb EBVCS2), and CD21 (B2, EBV receptor). Surface immunoglobulin was directly detected with fluoresceinated goat anti-human reagents.
Detection of EBV and HIV. In situ hybridization for EBV nucleic acid was performed with a cosmid clone, pM966/20 (16) , containing -25 kilobases (kb) of EBV sequence, encompassing 5' leader sequences and the gene for LMP. It was derivatized with digoxigenin-11-dUTP. Procedures for DNA probe labeling by the random-primer method, p-formaldehyde cell fixation, hybridization, and detection have been described elsewhere (17) .
The PCR was performed as described elsewhere, using primer pairs SK68/69 (env) and SK38/39 (gag) (18) . Reaction aliquots were run on a 1.5% agarose gel in the presence of ethidium bromide. Comparisons were made with amplified 7636 Medical Sciences: Laurence and Astrin DNA from U1.1A, a chronically infected promonocyte line containing two DNA copies of HIV per cell (17) .
Analysis of c-myc. In situ hybridization was performed with a digoxigenin-labeled 1.5-kb fragment containing the third exon of human c-myc (19) . Indirect immunofluorescence utilized a polyclonal rabbit anti-human Myc antiserum and a rhodamine-conjugated goat anti-rabbit immunoglobulin counterstain. An indication of relative amounts of c-myc RNA was obtained by using Quick-Blots (Schleicher & Schuell) (20) , in which mRNA is immobilized onto nitrocellulose, followed by hybridization with the digoxigeninlabeled c-myc exon 3 probe (21) . Controls for the amount of RNA bound to filters were performed on washed blots using 32P-labeled oligo(dT).
Transformation Assays in Vitro and in Vivo. Growth in soft agar was assayed by embedding 5 x 103 cells in 0.5 ml of RPMI 1640 medium plus 20% fetal calf serum and 0.3% agarose (Difco), contained in polystyrene macrowells. Duplicate plates were scored for colonies 12 days after seeding.
A xenotransplantation model was used to evaluate malignant potential in vivo (22) (23) (24) (25) (26) Two representative lines from one donor were used for the majority of experiments reported here, designated B-EBV and B-HIV for the viruses to which they had been exposed exogenously. Immortalized lines were also derived from the second donor, although these did not grow in low serum and were not further characterized. All lines were negative for T-cell CD3 and positive for membrane IgM.
Both B-HIV and B-EBV lines expressed-EBV-associated gene products LMP and CD23 and the EBV receptor (CD21). B-HIV cells expressed 3-to 5-fold higher levels of these antigens than did B-EBV. High LMP expression is associated with immortalization of B lymphocytes (5) and transformation of rat fibroblasts (27) . CD23 is an autocrine growth receptor thought to be required for LMP expression and cell immortalization and is induced by the EBV nuclear protein antigen gene EBNA-2 (28).
All cell lines were maintained in culture medium plus 10%o EBV and HIV Genomes. B-EBV cells contained EBVspecific transcripts and genome copy numbers below the sensitivity of our in situ assays ( Fig. 1 A and B) . In contrast, EBV genome number and gene expression were both markedly enhanced in all cells of the HIV immortalized population ( Fig. 1 C and D) .
By PCR, HIV proviral DNA was found solely in the B-HIV and B-HIV1 subline populations with, on average, one proviral copy per cell (Fig. 2) .
HIV replication was not detected in tests of supernatant fluids for HIV p24 Gag protein (17) or particulate reverse transcriptase activity (14) . However, thin-layer electron microscopy of these cells revealed few extracellular budding virions (data not shown).
Transformed Phenotype in Vitro. B-HIV1 cells grew logarithmically in medium containing 1% FBS (Fig. 3A) . This growth curve, prepared by doing daily cell counts of cultures maintained without addition of fresh medium, was similar to one obtained with the EBV+ Burkitt lymphoma line Raji (8) .
In contrast, B-EBV cells did not exhibit any significant growth under these conditions (Fig. 3A) . Conditioned medium prepared from 3-day-old B-HIV1 cultures and used in concentrations as high as 75% (vol/vol) did not stimulate growth of B-EBV cells (Fig. 3A) . Thus, the proliferative capacity of B-HIV1 cells appeared unrelated to lymphokine production or receptor shedding, factors that may recruit growth of nontransformed B cells in low serum (29, 30) .
To compensate for nutrient depletion, growth curves were repeated with replacement of one-half of the culture medium with fresh 1% FBS every 2-3 days. B-HIV1 cells continued to proliferate (Fig. 3B) (8) .
Malignant Potential in Vivo. B-EBV cells failed to elicit masses in either nude (0/6) or scid (0/9) mice over an observation period of 8 weeks. Between 8 and 12 weeks, 0/6 nude but 7/9 scid mice grew observable tumors. In contrast, B-HIV1 was highly tumorigenic. With these cells, 2 of 4 scid mice developed masses >2 cm in diameter by 4 weeks, with one animal bearing a visible tumor by 11 days postinoculation (Fig. 4A) . One of 6 nude mice developed a similar lesion. Histologic examination of B-HIV1 scid tumors revealed a highly malignant lymphoma of immunoblastic phenotype (Fig. 4 B and C) . These features included cells with multiple nucleoli and extensive invasion into muscle, endothelial vessels, and fat. In blinded fashion, they were diagnosed as "malignant lymphoma, probable Burkitt type." A partial karyotype of cells explanted from this tumor confirmed its human origin. In contrast, all tumors arising in four scid mice after inoculation with B-EBV cells were classified as "plasmacytomas."
HIV Activation of c-myc and EBV. Basal levels of c-myc transcripts (Fig. SA, lane 1) and protein (data not shown) were below the limits of detection of our assays in the B-EBV line. In contrast, B-HIV1 cells contained myc transcripts at levels comparable to that of Burkitt lymphoma cell line Raji (compare lanes 2 and 3). Control hybridizations using 32p_ labeled oligo(dT) confirmed that mRNA concentrations were equivalent in all lanes (Fig. 5) . In addition, B-HIV1 cells contained high levels of Myc nuclear protein (data not shown).
To determine whether this expression was a consequence of HIV infection, Raji cells were infected with HIV-1. Raji was chosen because of its elevated basal level of myc expression and because, despite having c-myc rearrangements, its myc promoters and >1 kb of upstream sequences are intact (31) . Exposure of Raji to HIV-1 for 3 days led to detectable increases in myc transcription in 100o of cells by in situ hybridization (Fig. 6 B and C) . Seven days postinfection an 8-to 16-fold enhancement in myc RNA expression was observed (Fig. 6A, compare lanes 1 and 2) . At this point, culture supernatants contained >20 ng of HIV-1 p24 gag antigen per ml, an indication that cells were productively infected with HIV, consistent with the ability of other groups to infect these cells despite their lack ofdetectable membrane CD4 (10). Exposure of Raji to equivalent concentrations of heat-inactivated HIV did not lead to upregulation of myc levels (data not shown). We also postulated that HIV infection of B cells harboring EBV directly induces expression of EBV transforming genes such as LMP. EBV transcription is dramatically upregulated in our B-HIV cell population, and EBV virion production in EBV+ B cells superinfected with HIV is enhanced in most (10), albeit not all (32) (9), and circulating B cells may contain HIV provirus at levels comparable to those of CD4+ T cells (34) .
Deregulation of c-myc together with expression of certain EBV proteins may be necessary and sufficient components for malignant transformation (8, 27) . Our data indicate that HIV itself can initiate or potentiate both events, which then lead to tumorigenic growth patterns in B lymphocytes. The experiments demonstrating HIV induction of c-myc in B cells are consistent with the findings of others (35) that myc deregulation occurs after HIV infection of monocytic cells, with levels of viral RNA correlated to levels of myc expression. This effect may be cell lineage restricted, as upregulation of c-myc has not been reported in the few T-cell lines examined.
The ability of freshly isolated EBV+ B-cell lines from normal individuals to proliferate in 1% serum, clone in agar, and rapidly form invasive tumors in scid mice is likely to be related to HIV infection in our cells. B-cell lines are usually not tumorigenic in scid mice (23) . Large inocula of EBV+ B-cell lines (24, 25, 36) and recently shown in a direct comparison of groups of scid mice administered either EBV-infected peripheral lymphocytes, EBV-immortalized cell lines, or Burkitt lymphoma lines (24) .
An important question is the relevance of this model to lymphomas found in AIDS patients. Up to 12% of HIVseropositive individuals in the U.S. develop clinically aggressive B-cell non-Hodgkin lymphomas (37) . A frequent role for c-myc activation in the pathogenesis of these lymphomas is documented by rearrangements of this protooncogene in many specimens (38) (39) (40) . Both EBV expression and c-myc deregulation occur in at least 30%o of these tumors. It is frequently hypothesized that these lymphomas arise as HIVmediated immune suppression permits reactivation of latent EBV infection in B cells. This is thought to be followed by uncontrolled polyclonal proliferation, which increases the probability of a recombinase error and eventually leads to c-myc activation. However, development of these lymphomas may not correlate with changes in absolute CD4' T-cell count or CD4/CD8 T-cell ratios (41) , which appear to be the best indicators of immune suppression in HIV infection. Indeed, 40% of all HIV-linked lymphomas occur in asymptomatic individuals (41) . We speculate, based on our in vitro model, that HIV plays a role in initiating and maintaining transformation of B cells through a combination of c-myc deregulation with activation of EBV transforming proteins.
An ostensible limitation of this model is that HIV-1 sequences have not been found in biopsy samples of HIVassociated lymphomas by Southern analysis (4, 42, 43) . PCR reveals levels of HIV only 10-fold greater than would be predicted from infiltrating T cells in the pathologic specimens (44, 45) . This discrepancy may be explained in several ways.
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